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amplification. The principle of prion-like
polymerization seems to be conserved
in signal transduction because a fungal
NOD-like pattern recognition receptor
also induces conversion of a fungal prion
(Cai et al., 2014). Moreover, filamentous
signaling complexes with DD modules
are observed in other inflammatory cas-
cades such as antigen receptor signaling
through CARD11/BCL10/MALT1 (Qiao
et al., 2013) or in the Rig-I/MAVS
pathway (Hou et al., 2011). Still, many
DD-containing immune adapters, in-
cluding MyD88, do not form unrestrained
polymers but rather form limited oligo-
mers with presumably reversible organi-
zation (Lin et al., 2010). The biophysical
characteristics that dictate limited olig-
omer versus self-propagating polymer
formation remain to be defined.
Of note, not all inflammasomes utilize
ASC. The sensor NLRC4, for instance,
can activate caspase-1 independent of
ASC after Salmonella typhimurium infec-tion. Whether such mechanisms also
involve prion-like protein conversion is
unclear. Finally, because aberrant inflam-
masome activation is deleterious to the
host (Schroder and Tschopp, 2010), it
must be counterbalanced to maintain
homeostasis. Classical inflammatory
pathways that are controlled by pro-
tein kinases or ubiquitin ligases are
negatively regulated via phosphatases
and de-ubiquitinases (Ruland, 2011).
The literature indicates that selective
autophagy could remove filamentous
CARD11/BCL10/MALT1 signalosomes
after T cell activation (Paul et al., 2012).
In the future, it will be important to define
whether similar mechanisms could also
disassemble activated inflammasomes.ACKNOWLEDGMENTS
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Synonymous mutations do not alter amino acids and are generally considered nonfunctional in
cancer. Supek et al. now present a compelling analysis suggesting that such silent mutations
can be oncogenic by altering transcript splicing and thereby affecting protein function.Sporadic cancer is thought to arise from a
cell of origin with accumulated somatic
mutations. With thousands of cancer
genomes and exomes sequenced, dif-
ferent categories of genomic alterations,
such as somatic point mutations, loss
or gain of chromosome material, and
structural genome rearrangements, have
been identified by comparing DNA from
tumor cells with that from matching
normal tissues. Point mutations are clas-
sified as synonymous versus nonsynony-mous based on their ability to alter the
encoded amino acids and thus affect
protein function. Synonymous or silent
mutations are categorized as passenger
events because they do not modify the
protein sequence and are thus consid-
ered functionally irrelevant, although their
potential involvement in tumorigenesis
has been suspected (Gartner et al.,
2013). In this issue, Ben Lehner and col-
leagues revisit this common perception
of synonymous mutations in cancer(Supek et al., 2014). By analyzing the
catalog of somatic mutations detected in
3,851 cancer exomes and more than
400 whole genomes from 19 tumor types,
they observed a 1.23- to 1.3-fold enrich-
ment of silent mutations in oncogenes,
but not in tumor suppressor genes,
when compared to a set of noncancer
genes with matching genomic features,
including GC content, mRNA expression
levels across tissues, and replication
timing. As a reference, the enrichment, March 13, 2014 ª2014 Elsevier Inc. 1129
Figure 1. Synonymous Mutations Can Alter Pre-mRNA Splicing
(A) A synonymous mutation leads to the gain of an exonic splicing enhancer motif. Consequently, binding of the splicing regulator SRSF1 is enhanced, resulting
in the inclusion of an otherwise skipped exon.
(B) A synonymous mutation deactivates an exonic splicing silencer motif, thereby abolishing the binding of hnRNP splicing regulators.of missense mutations was 2.5-fold
compared to the matching gene set. Syn-
onymous mutations were nonrandomly
distributed across the gene territory, and
they preferentially targeted evolutionarily
conserved sites. An enrichment of
silent mutations was observed near exon
boundaries, suggesting a potential effect
on elements that regulate pre-mRNA
transcript splicing, such as exonic splic-
ing enhancer (ESE) and loss of silencer
(ESS) motifs. Indeed, when using RNA-
sequencing data to evaluate transcript
level variability, genes with synonymous
mutations exhibited an increase in differ-
ential exon usage compared to other
samples of the same tissue type (Figure 1).
Association between silent coding vari-
ants and transcript isoforms was not
detected in tumor suppressor genes,
except for TP53, where synonymous
mutations were found to be associated
with inactive splice sites.
Synonymous mutations account for
20%–40% of somatic mutations detected1130 Cell 156, March 13, 2014 ª2014 Elseviein cancer exomes (Imielinski et al., 2012;
Lawrence et al., 2013). Commonly as-
sumed to be spurious passenger events,
these silent mutations are used to esti-
mate background mutation frequency for
genomic analysis. Algorithms such as
MutSigCV (Lawrence et al., 2013) and
MuSiC (Dees et al., 2012) rely on the back-
groundmutation rate to determine the sig-
nificance of gene mutations, which is the
probability that mutations in a certain
gene are overrepresented and driving
cancer. The observations by Supek et al.
implicate that the background mutation
frequency in oncogenes has been overes-
timated, whereas the incidence of func-
tional mutations in oncogenes has been
underestimated. Selective enrichment of
synonymous mutations may represent
an additional mechanism for oncogene
activation that, if considered, could poten-
tially enhance the power of finding novel
oncogenes from the currently available
sequencing data. However, for this partic-
ular study, as themajority of inferences byr Inc.Supek et al. are based on oncogenes that
are also targeted by missense mutations,
it seems that taking the synonymous
events into consideration would most
likely strengthen previous observa-
tions, as opposed to identify many novel
oncogenes.
Efforts to characterize the cancer
genome have led to the identification of
driver genes in many cancer types. How-
ever, driver gene mutations cannot be
detected in a substantial percentage of
tumor samples, even in tumor types with
a high mutation frequency, such as lung
adenocarcinoma (Imielinski et al., 2012).
Several explanations have been pro-
posed. For instance, we may simply
have not detected all driver gene muta-
tions. Recent saturation analysis sug-
gested that up to 5,000 cancer-normal
pairs are needed to comprehensively
characterize the long distribution tail of
less frequently mutated cancer drivers
(Lawrence et al., 2014). In addition, mech-
anisms such as epigenetic alterations
may complement somatic mutations in
promoting tumor growth, as is the case
for the mutually exclusive pattern of aber-
rant DNA promoter methylation and so-
matic mutation of the Von Hippel-Lindau
gene in clear cell renal cell carcinoma
(TCGA, 2013). Functionally relevant syn-
onymous mutations, long ignored in
cancer genomics, occur in a mutually
exclusive fashion with nonsynonymous
mutations in the same genes, and may
provide an alternate mode of oncogene
activation to help explain the cause of
tumorigenesis in certain tumor samples
in which nonsynonymous driver gene
mutations cannot be detected.
The mechanism by which synonymous
mutations are able to alter oncogene ac-
tivity, modulation of the splicing machin-
ery, may open avenues for precisionmed-
icine. The presence of a synonymous
mutation in a cancer driver gene may
be an indication of oncogene addic-
tion, thereby presenting a therapeutically
exploitable opportunity for treating the
relevant tumors. Supek et al. found
that synonymous mutations were asso-
ciated with increased exon expression
variability, suggesting the presence
of tumor-cell-specific transcripts. Small
interfering RNAs (siRNAs) can mediate
target mRNA cleavage and degradation
with a high specificity and hold promise
for effective cancer-cell-specific gene
silencing (Tabernero et al., 2013). In
particular, more than 40% of ESE-altering
synonymous mutations were found to be
associated with the known binding site
of the proto-oncogene SRSF1 (SF2/ASF)
splicing factor, and ESS-interfering syn-onymous mutations were found to cluster
near the binding site of HNRNPH2, a
splicing factor that has been implicated
in drug resistance (Stark et al., 2011).
These findings suggest a potential
future direction for therapeutic interven-
tion, which is to target the splicing regula-
tory factors instead of individual genes
(Grosso et al., 2008).
The analysis in the present study dem-
onstrates the power of a large collection
of publicly available sequence data, pre-
dominantly empowered by multi-institu-
tional efforts such as The Cancer Genome
Atlas project (http://cancergenome.nih.
gov/) and International Cancer Genome
Consortium project (http://icgc.org/).
For the cancer research community, this
work invites a new take on synonymous
mutations. More importantly, it calls
for a systematic functional assessment
and characterization of these mutations
in order to discriminate synonymous
mutations with functional consequences
from those that are truly futile. The find-
ings described here suggest that synony-
mous mutations should be included
in both quantitative modeling of cancer
gene associations and clinical utility
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